Dimethyldioctadecylammonium bromide

Synonyms	DDAB; N,N-dimethyl-N-octadecyloctadecan-1-aminium bromide; 1-Octadecanaminium, N,N-dimethyl-N-octadecyl-, bromide; Dimethyldistearylammonium bromide; Distearyldimethylammonium bromide; Dimethyldioctadecylazanium bromide; Dioctadecyldimethylammonium bromide; di-n-Octadecyldimethylammonium bromide; N,N-Distearyl-N,N-dimethylammonium bromide; 18:0 DDAB; DODAB
IUPACName	dimethyl(dioctadecyl)azanium;bromide
CanonicalSMILES	CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC.[Br-]
InChI	InChI=1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1
InChIKey	PSLWZOIUBRXAQW-UHFFFAOYSA-M
BoilingPoint	159-160 °C at 760 mmHg
MeltingPoint	151-157 °C
Purity	≥98%
Density	1.05 g/cm3
Solubility	Soluble in Acetone, Acetonitrile, Ethanol, Methanol, Water
ExactMass	629.547
Hygroscopic	No
LightSensitive	No
PercentComposition	C 72.34%, H 12.78%, Br 12.66%, N 2.22%
Pictogram	Irritant
Signal	Warning
PrecautionaryStatementCodes	P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501

1. Lou G, Anderluzzi G, Tandrup Schmidt S, Woods S, Gallorini S, Brazzoli M, Giusti F, Ferlenghi I, Johnson R, Roberts CW, O'Hagan DT, Baudner BC, Perrie Y. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J Control Release. 2020 Jun 30:S0168-3659(20)30362-X. doi: 10.1016/j.jconrel.2020.06.027. Epub ahead of print. PMID: 32619745. PubMed ID: 32619745.
2. Lee H, Jiang D, Pardridge WM. Lyoprotectant Optimization for the Freeze-Drying of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery. Mol Pharm. 2020 Apr 29. doi: 10.1021/acs.molpharmaceut.0c00310. Epub ahead of print. PMID: 32315188. PubMed ID: 32315188.
3. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020 Apr;15(4):313-320. doi: 10.1038/s41565-020-0669-6. Epub 2020 Apr 6. PMID: 32251383. PubMed ID: 32251383.
4. Chatzikleanthous D, Schmidt ST, Buffi G, Paciello I, Cunliffe R, Carboni F, Romano MR, O'Hagan DT, D'Oro U, Woods S, Roberts CW, Perrie Y, Adamo R. Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes. J Control Release. 2020 Apr 2:S0168-3659(20)30211-X. doi: 10.1016/j.jconrel.2020.04.001. Epub ahead of print. PMID: 32247804. PubMed ID: 32247804.
5. Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017 Mar 7;35(10):1395-1402. doi: 10.1016/j.vaccine.2017.01.079. Epub 2017 Feb 9. PMID: 28190740. PubMed ID: 28190740.
6. Derrick SC, Yabe I, Morris S, Cowley S. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice. Clin Vaccine Immunol. 2016 Jul 5;23(7):638-47. doi: 10.1128/CVI.00232-16. PMID: 27226281; PMCID: PMC4933783. PubMed ID: 27226281.
7. Rose F, Wern JE, Ingvarsson PT, van de Weert M, Andersen P, Follmann F, Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release. 2015 Jul 28;210:48-57. doi: 10.1016/j.jconrel.2015.05.004. Epub 2015 May 6. PMID: 25957906. PubMed ID: 25957906.
8. Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, Jing Y, Zhang Z, Yue T, Zhou L, Fan X. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother. 2015;11(6):1456-64. doi: 10.1080/21645515.2015.1037057. PMID: 25905680; PMCID: PMC4514263. PubMed ID: 25905680.
9. Gallez A, Palazzo C, Blacher S, Tskitishvili E, Noël A, Foidart JM, Evrard B, Pequeux C, Piel G. Liposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17β-estradiol: An innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor α. Int J Pharm. 2020 Jan 5;573:118861. doi: 10.1016/j.ijpharm.2019.118861. Epub 2019 Nov 22. PubMed ID: 31765774.
10. Faria MJ, Machado R, Ribeiro A, Gonçalves H, Real Oliveira MECD, Viseu T, das Neves J, Lúcio M. Rational Development of Liposomal Hydrogels: A Strategy for Topical Vaginal Antiretroviral Drug Delivery in the Context of HIV Prevention. Pharmaceutics. 2019 Sep 18;11(9). pii: E485. doi: 10.3390/pharmaceutics11090485. PubMed ID: 31540519.